大肠癌筛检和诊断市场—全球产业规模、份额、趋势、机会和预测（按筛检、诊断、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球大肠癌筛检和诊断市场价值为 150.8 亿美元，预计到 2030 年将达到 206.3 亿美元，复合年增长率为 5.34%。随着全球对癌症预防、早期发现和诊断技术进步的认识不断提高，全球大肠癌筛检和诊断市场正在经历显着增长。大肠直肠癌发生率不断上升，尤其是 50 岁及以上人群，这推动了对早期和准确筛检方法的需求。政府和医疗保健组织正在进行宣传活动，强调常规筛检的重要性，导致检测量激增。公私部门合作伙伴关係和医疗保健资助计划使人们能够更多地获得诊断服务，特别是在服务不足的人群中。此外，粪便免疫化学测试 (FIT)、粪便 DNA 测试和血液诊断等非侵入性筛检方法的接受度不断提高，使得筛检更容易被更广泛的患者群体接受。

技术创新在重塑市场格局中发挥着至关重要的作用。基于人工智慧的大肠镜系统、数位病理工具和液体活检技术的开发正在提高检测准确性并减少侵入性手术的需求。机器学习与诊断影像的结合正在帮助临床医生更有效地识别息肉和早期肿瘤。人们对家庭和即时诊断检测选项的兴趣日益浓厚，这也改变了患者的行为，越来越多的人选择方便、自主的诊断工具。领先的诊断公司正在投资研究，以增强基于生物标记的筛选方法，提供更高的特异性和敏感性，从而开闢新的收入来源。包括大肠直肠癌标记在内的多癌症检测面板的出现预计将进一步刺激行业内的创新和竞争。

关键市场驱动因素

技术进步

主要市场挑战

假阳性和过度诊断

主要市场趋势

转向非侵入性测试

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球大肠癌筛检与诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 透过筛检（粪便检查、大肠镜检查、乙状结肠镜检查等）
  • 透过诊断（生物标记测试、大肠镜检查）
  • 按最终使用者（医院和诊所、临床实验室等）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区大肠直肠癌筛检与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲大肠癌筛检与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第八章：北美大肠癌筛检与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第九章：南美洲大肠癌筛检与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲大肠直肠癌筛检和诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球大肠直肠癌筛检与诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc
• FUJIFILM Holdings Corporation
• Novigenix SA
• QuidelOrtho Corporation
• Olympus Corporation
• Lepu Medical Technology (Beijing) Co., Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Colorectal Cancer Screening and Diagnostic Market was valued at USD 15.08 Billion in 2024 and is expected to reach USD 20.63 Billion in the forecast period with a CAGR of 5.34% through 2030. The Global Colorectal Cancer Screening and Diagnostic Market is witnessing significant growth due to increasing global awareness regarding cancer prevention, early detection, and advancements in diagnostic technologies. Rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Governments and healthcare organizations are launching awareness campaigns that emphasize the importance of routine screening, contributing to a surge in testing volumes. Public-private partnerships and healthcare funding initiatives are enabling greater access to diagnostic services, especially in underserved populations. Moreover, the growing acceptance of non-invasive screening methods such as fecal immunochemical tests (FIT), fecal DNA tests, and blood-based diagnostics is making screening more accessible and acceptable to a broader patient demographic.

Technological innovations are playing a vital role in reshaping the market landscape. The development of AI-based colonoscopy systems, digital pathology tools, and liquid biopsy technologies is improving detection accuracy and reducing the need for invasive procedures. Integration of machine learning in diagnostic imaging is assisting clinicians in identifying polyps and early-stage tumors more effectively. Rising interest in home-based and point-of-care testing options is also transforming patient behavior, with more individuals opting for convenient, self-administered diagnostic tools. Leading diagnostic companies are investing in research to enhance biomarker-based screening approaches that offer higher specificity and sensitivity, which is opening new revenue streams. The emergence of multi-cancer detection panels, which include colorectal cancer markers, is expected to further stimulate innovation and competition within the industry.

Key Market Drivers

Advancements in Technology

High-definition (HD) colonoscopy utilizes advanced imaging technology to provide clearer and more detailed images of the colon, enhancing the detection of precancerous polyps and early-stage colorectal cancer during procedures. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were 142,462 reported cases of colon and rectum cancer in the United States, emphasizing the importance of improved detection methods.

Key Market Challenges

False Positives and Over diagnosis

False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Over diagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Over diagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life.

Key Market Trends

Shift Towards Non-Invasive Tests

Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.

Key Market Players

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Novigenix SA
• FUJIFILM Holdings Corporation
• Olympus Corporation
• QuidelOrtho Corporation

Report Scope:

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, By Screening:

• Stool-Based Test
• Colonoscopy and Sigmoidoscopy
• Others

Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:

• Biomarker Test
• Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, By End User:

• Hospitals and Clinics
• Clinical Laboratories
• Others

Colorectal Cancer Screening and Diagnostic Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Screening and Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
  • 5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
  • 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Screening
  • 6.2.2. By Diagnostics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Screening
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By End User
  • 6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Screening
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Screening
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Screening
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Screening
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By End User

7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Screening
  • 7.2.2. By Diagnostics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Screening
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Screening
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Screening
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Screening
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Screening
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By End User

8. North America Colorectal Cancer Screening and Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Screening
  • 8.2.2. By Diagnostics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Screening
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Screening
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Screening
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By End User

9. South America Colorectal Cancer Screening and Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Screening
  • 9.2.2. By Diagnostics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Screening
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Screening
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Screening
      • 9.3.3.2.2. By Diagnostics
      • 9.3.3.2.3. By End User

10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Screening
  • 10.2.2. By Diagnostics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Screening
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Screening
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Screening
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Clinical Genomics Technologies Pty Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Danaher Corporation
• 16.3. DiaCarta, Inc
• 16.4. Eiken Chemical Co., Ltd.
• 16.5. Epigenomics AG
• 16.6. Freenome Holdings, Inc.
• 16.7. Guardant Health, Inc
• 16.8. FUJIFILM Holdings Corporation
• 16.9. Novigenix SA
• 16.10. QuidelOrtho Corporation
• 16.11. Olympus Corporation
• 16.12. Lepu Medical Technology (Beijing) Co., Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer